Indeed, a number of animal studies have supported the hypothesis that increasing ratios of EETs to DHETs through genetic deletion or pharmacological inhibition of sEH offers protection against experimental cerebral ischemia [15, 16], parkinsonism [17], and seizures [18]. Here, EPHX2 is linked to Parkinson disease.